Platelet Purinergic Receptors in Thrombosis and Inflammation

Abstract

It took approximately 40 years from the seminal identification of adenosine diphosphate (ADP) as the factor R, an agent derived from red blood cells inducing platelet adhesion to glass, to the completion of the repertoire of its receptors on platelets and its importance in haemostasis and thrombosis. ADP, either derived from red blood cells or released by platelets themselves, stimulates platelets via two G protein-coupled receptors, P2Y₁ and P2Y₁₂. In addition, adenosine triphosphate, also contained in the platelet dense granules, activates the P2X₁ cation channel. Each of these receptors plays a specific role during platelet activation and aggregation, with relevance to haemostasis, thrombosis and various inflammatory processes where platelets are involved including chronic responses such as atherosclerosis or acute responses such as sepsis, endotoxaemia or allergic asthma. Finally, platelets also express P2Y₁₄, a receptor activated by released uridine diphosphate glucose. Although devoid of any known role in haemostasis, this receptor seems to play a specific role in neutrophil chemotaxis.

Keywords

nucleotides - platelets - thrombosis - inflammation - atherosclerosis

Disclosures

None.

• References

• 1 Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
• 2 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
• 3 Maffrand JP, Bernat A, Delebassée D, Defreyn G, Cazenave JP, Gordon JL. ADP plays a key role in thrombogenesis in rats. Thromb Haemost 1988; 59 (02) 225-230
• 4 Cattaneo M, Canciani MT, Lecchi A. , et al. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990; 75 (05) 1081-1086
• 5 Dovlatova N, Wijeyeratne YD, Fox SC. , et al. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor. Thromb Haemost 2008; 100 (02) 261-270
• 6 Hechler B, Léon C, Vial C. , et al. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998; 92 (01) 152-159
• 7 Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403 (01) 26-30
• 8 Waldo GL, Harden TK. Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol Pharmacol 2004; 65 (02) 426-436
• 9 Crittenden JR, Bergmeier W, Zhang Y. , et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004; 10 (09) 982-986
• 10 Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006; 46: 277-300
• 11 Hollopeter G, Jantzen HM, Vincent D. , et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409 (6817): 202-207
• 12 Zhang FL, Luo L, Gustafson E. , et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 2001; 276 (11) 8608-8615
• 13 Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103 (03) 858-866
• 14 Trumel C, Payrastre B, Plantavid M. , et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94 (12) 4156-4165
• 15 Kauffenstein G, Hechler B, Cazenave JP, Gachet C. Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost 2004; 2 (11) 1980-1988
• 16 Cattaneo M. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117 (07) 2102-2112
• 17 Gremmel T, Michelson AD, Frelinger III AL, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018; 2 (03) 439-449
• 18 Gachet C. P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal 2012; 8 (03) 609-619
• 19 Hechler B, Gachet C. Purinergic receptors in thrombosis and inflammation. Arterioscler Thromb Vasc Biol 2015; 35 (11) 2307-2315
• 20 Hao Y, Wang L, Chen H. , et al. Targetable purinergic receptors P2Y12 and A2b antagonistically regulate bladder function. JCI Insight 2019; 4 (16) 122112
• 21 Gratacap MP, Guillermet-Guibert J, Martin V. , et al. Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions. Adv Enzyme Regul 2011; 51 (01) 106-116
• 22 Stefanini L, Paul DS, Robledo RF. , et al. RASA3 is a critical inhibitor of RAP1-dependent platelet activation. J Clin Invest 2015; 125 (04) 1419-1432
• 23 Lecchi A, Femia EA, Paoletta S. , et al. Inherited dysfunctional platelet P2Y₁₂ receptor mutations associated with bleeding disorders. Hamostaseologie 2016; 36 (04) 279-283
• 24 Hechler B, Lenain N, Marchese P. , et al. A role of the fast ATP-gated P2 × 1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003; 198 (04) 661-667
• 25 Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Hemost 2005; 31 (02) 168-173
• 26 Oury C, Toth-Zsamboki E, Van Geet C. , et al. A natural dominant negative P2 × 1 receptor due to deletion of a single amino acid residue. J Biol Chem 2000; 275 (30) 22611-22614
• 27 Gachet C. Antiplatelet drugs: which targets for which treatments?. J Thromb Haemost 2015; 13 (Suppl. 01) S313-S322
• 28 Zhang J, Zhang K, Gao ZG. , et al. Agonist-bound structure of the human P2Y12 receptor. Nature 2014; 509 (7498): 119-122
• 29 Zhang K, Zhang J, Gao ZG. , et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 2014; 509 (7498): 115-118
• 30 Fabre JE, Nguyen M, Latour A. , et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5 (10) 1199-1202
• 31 Léon C, Hechler B, Freund M. , et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 1999; 104 (12) 1731-1737
• 32 Léon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation 2001; 103 (05) 718-723
• 33 Lenain N, Freund M, Léon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost 2003; 1 (06) 1144-1149
• 34 Hechler B, Nonne C, Roh EJ. , et al. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther 2006; 316 (02) 556-563
• 35 Zhang D, Gao ZG, Zhang K. , et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 2015; 520 (7547): 317-321
• 36 Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood 2014; 123 (18) 2759-2767
• 37 Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature 2014; 509 (7500): 310-317
• 38 Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Lüscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12 (02) 113-122
• 39 Evans DJ, Jackman LE, Chamberlain J. , et al. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009; 119 (01) 116-122
• 40 Li D, Wang Y, Zhang L. , et al. Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2012; 32 (08) e81-e89
• 41 West LE, Steiner T, Judge HM, Francis SE, Storey RF. Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovasc Res 2014; 102 (03) 429-435
• 42 Abele S, Spriewald BM, Ramsperger-Gleixner M. , et al. Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts. Transplantation 2009; 87 (02) 207-216
• 43 Harada K, Matsumoto Y, Umemura K. Adenosine diphosphate receptor P2Y12-mediated migration of host smooth muscle-like cells and leukocytes in the development of transplant arteriosclerosis. Transplantation 2011; 92 (02) 148-154
• 44 Paruchuri S, Tashimo H, Feng C. , et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206 (11) 2543-2555
• 45 Cattaneo M. The platelet P2 receptors in inflammation. Hamostaseologie 2015; 35 (03) 262-266
• 46 Amison RT, Momi S, Morris A. , et al. RhoA signaling through platelet P2Y₁ receptor controls leukocyte recruitment in allergic mice. J Allergy Clin Immunol 2015; 135 (02) 528-538
• 47 Hagiwara S, Iwasaka H, Hasegawa A. , et al. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 2011; 35 (03) 289-292
• 48 Liverani E, Rico MC, Tsygankov AY, Kilpatrick LE, Kunapuli SP. P2Y12 receptor modulates sepsis-induced inflammation. Arterioscler Thromb Vasc Biol 2016; 36 (05) 961-971
• 49 Léon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003; 23 (10) 1941-1947
• 50 Zerr M, Hechler B, Freund M. , et al. Major contribution of the P2Y₁receptor in purinergic regulation of TNFα-induced vascular inflammation. Circulation 2011; 123 (21) 2404-2413
• 51 Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP, Gachet C. Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors. Circulation 2008; 118 (07) 754-763
• 52 Liu R, Ma S, Lu Z, Shen H, Sun L, Wei M. The ADP antagonist MRS2179 regulates the phenotype of smooth muscle cells to limit intimal hyperplasia. Cardiovasc Drugs Ther 2015; 29 (01) 23-29
• 53 Marques-da-Silva C, Burnstock G, Ojcius DM, Coutinho-Silva R. Purinergic receptor agonists modulate phagocytosis and clearance of apoptotic cells in macrophages. Immunobiology 2011; 216 (1–2): 1-11
• 54 Darbousset R, Delierneux C, Mezouar S. , et al. P2 × 1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice. Blood 2014; 124 (16) 2575-2585
• 55 Ilkan Z, Watson S, Watson SP, Mahaut-Smith MP. P2 × 1 receptors amplify FcγRIIa-induced Ca2+ increases and functional responses in human platelets. Thromb Haemost 2018; 118 (02) 369-380
• 56 Lecut C, Faccinetto C, Delierneux C. , et al. ATP-gated P2 × 1 ion channels protect against endotoxemia by dampening neutrophil activation. J Thromb Haemost 2012; 10 (03) 453-465
• 57 Maître B, Magnenat S, Heim V. , et al. The P2 × 1 receptor is required for neutrophil extravasation during lipopolysaccharide-induced lethal endotoxemia in mice. J Immunol 2015; 194 (02) 739-749
• 58 El Mdawar MB, Maître B, Magnenat S, Gachet C, Hechler B, de la Salle H. The ATP-gated P2X₁ ion channel contributes to the severity of antibody-mediated transfusion-related acute lung injury in mice. Sci Rep 2019; 9 (01) 5159
• 59 Sesma JI, Weitzer CD, Livraghi-Butrico A. , et al. UDP-glucose promotes neutrophil recruitment in the lung. Purinergic Signal 2016; 12 (04) 627-635
• 60 Amison RT, Arnold S, O'Shaughnessy BG. , et al. Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y₁ and P2Y₁₄ receptors in mice. Pulm Pharmacol Ther 2017; 45: 62-68